BioSpace News Archive

Zealand Pharma A/S a biotechnology company aspiring to change lives through the development of innovative peptide-based medicines, announced that members of its senior management team are scheduled to participate virtually in the Jefferies Virtual Healthcare Conference.

Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that an article titled, “Long Term Safety, Tolerability, and Efficacy of Intracutaneous Zolmitriptan (M207) in the Acute Treatment of Migraine” was published in The Journal of Headache and Pain.

Revance Therapeutics, Inc., a biotechnology company focused on innovative aesthetic and therapeutic offerings, announced that the company’s President and Chief Executive Officer, Mark Foley, is scheduled to participate in fireside chats at the following conferences:

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will host a MISSION Phase 1b data update call for investors and analysts during the European Congress of Rheumatology (EULAR 2021) on Wednesday, June 2, 2021 at 4:30 p.m. ET.

Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following virtual investor conferences during the month of June.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present at the 2021 Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 11:30 a.m. ET.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its senior management team will provide a company overview and business and financial updates at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021, at 1:00 p.m. ET / 6:00 p.m. IST.

(Euronext – FR0010557264 – AB) communicated the results from phase 3 study evaluating masitinib in prostate cancer during the webcast that was held on May 25, 2021.

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company currently focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer and blood disorders, invites investors to review the Company’s shareholder update conference call presentation via its website,

Strategic expansion represents significant investment to bring pediatric health care services closer to home for West Valley families